Growth disadvantage associated with centrosome amplification drives population-level centriole number homeostasis.


Journal

Molecular biology of the cell
ISSN: 1939-4586
Titre abrégé: Mol Biol Cell
Pays: United States
ID NLM: 9201390

Informations de publication

Date de publication:
15 11 2020
Historique:
pubmed: 24 9 2020
medline: 14 7 2021
entrez: 23 9 2020
Statut: ppublish

Résumé

The centriole duplication cycle normally ensures that centriole number is maintained at two centrioles per G1 cell. However, some circumstances can result in an aberrant increase in centriole number-a phenotype that is particularly prevalent in several types of cancer. Following an artificial increase in centriole number without tetraploidization due to transient overexpression of the kinase PLK4, human cells return to a normal centriole number during the proliferation of the population. We examine the mechanisms responsible for this return to normal centriole number at the population level in human retinal pigment epithelial cells. We find that the return to normal centriole number in the population of induced cells cannot be explained by limited duplication of centrioles, instability of extra centrioles, or by grossly asymmetric segregation of extra centrioles in mitosis. However, cells with extra centrioles display heterogenous phenotypes including extended cell cycle arrest, longer interphase durations, and death, which overall results in a proliferative disadvantage relative to normal cells in the population. Although about half of cells with extra centrioles in a population were able to divide, the extent of the disadvantages conferred by other fates is sufficient to account for the observed rate of return to normal centriole number. These results suggest that only under conditions of positive selection for cells with extra centrioles, continuous generation of such centrioles, or alleviation of the disadvantageous growth phenotypes would they be maintained in a population.

Identifiants

pubmed: 32966175
doi: 10.1091/mbc.E19-04-0195
pmc: PMC7927180
doi:

Substances chimiques

Cell Cycle Proteins 0
PLK4 protein, human EC 2.7.1.-
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2646-2656

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM130286
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007276
Pays : United States

Références

J Cell Biol. 1982 Sep;94(3):549-56
pubmed: 7130271
J Cell Biol. 2010 Nov 15;191(4):721-9
pubmed: 21059850
Dev Cell. 2007 Aug;13(2):190-202
pubmed: 17681131
Nature. 2009 Jul 9;460(7252):278-82
pubmed: 19506557
Nat Commun. 2013;4:1775
pubmed: 23653187
EMBO J. 2011 Oct 21;30(23):4790-804
pubmed: 22020124
Philos Trans R Soc Lond B Biol Sci. 2014 Sep 5;369(1650):
pubmed: 25047621
Nat Rev Mol Cell Biol. 2015 Oct;16(10):611-24
pubmed: 26373263
Nat Rev Mol Cell Biol. 2018 May;19(5):297-312
pubmed: 29363672
Nature. 2006 Aug 24;442(7105):947-51
pubmed: 16862117
Nature. 2005 Oct 13;437(7061):1043-7
pubmed: 16222300
Science. 2015 Jun 5;348(6239):1155-60
pubmed: 25931445
J Cell Sci. 2004 Apr 1;117(Pt 9):1619-30
pubmed: 15075224
Curr Biol. 2015 Mar 30;25(7):879-89
pubmed: 25772448
Oncogene. 2003 Jun 19;22(25):3859-66
pubmed: 12813459
Genes Dev. 2017 Jan 1;31(1):34-45
pubmed: 28130345
J Biol Chem. 2004 Jun 25;279(26):27549-59
pubmed: 15102862
Int J Biol Sci. 2011;7(8):1122-44
pubmed: 22043171
J Biol Methods. 2014;1(2):
pubmed: 25606571
Genes Dev. 2008 Aug 15;22(16):2189-203
pubmed: 18662975
J Cell Biol. 2011 May 16;193(4):727-39
pubmed: 21576395
PLoS Comput Biol. 2019 Mar 11;15(3):e1006832
pubmed: 30856170
Elife. 2015 May 05;4:
pubmed: 25942454
Nat Cell Biol. 2005 Feb;7(2):115-25
pubmed: 15665853
J Cell Biol. 2018 Jan 2;217(1):195-209
pubmed: 29133484
Curr Biol. 2005 Dec 20;15(24):2199-207
pubmed: 16326102
Genes Dev. 2012 Dec 15;26(24):2684-9
pubmed: 23249732
Nat Cell Biol. 2008 Jun;10(6):748-51
pubmed: 18469805
Blood. 1993 Nov 1;82(9):2617-23
pubmed: 8219216
Nat Rev Cancer. 2002 May;2(5):342-50
pubmed: 12044010
Cell. 2008 Jun 13;133(6):1032-42
pubmed: 18555779
Cell Death Differ. 2019 Jan;26(2):199-212
pubmed: 30538286
Cell. 2014 Aug 14;158(4):833-848
pubmed: 25126788
Dev Cell. 2007 Aug;13(2):203-13
pubmed: 17681132
Dev Cell. 2015 Oct 26;35(2):222-35
pubmed: 26481051
Cell. 2009 Nov 13;139(4):663-78
pubmed: 19914163
Nat Cell Biol. 2005 Nov;7(11):1140-6
pubmed: 16244668
Nat Cell Biol. 2011 Oct 03;13(10):1154-60
pubmed: 21968988
Dev Cell. 2002 Sep;3(3):339-50
pubmed: 12361598
Elife. 2017 Sep 14;6:
pubmed: 28906251
Elife. 2020 Apr 29;9:
pubmed: 32347795
Sci Rep. 2020 Jun 4;10(1):9152
pubmed: 32499568

Auteurs

Roberta Sala (R)

Department of Biology, Stanford University, Stanford, CA 94305.

K C Farrell (KC)

Department of Biology, Stanford University, Stanford, CA 94305.

Tim Stearns (T)

Department of Biology, Stanford University, Stanford, CA 94305.
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH